A meta-analysis of the association between adherence to drug therapy and mortality

Scot H Simpson, Dean T Eurich, Sumit R Majumdar, Rajdeep S Padwal, Ross T Tsuyuki, Janice Varney, Jeffrey A Johnson

Abstract

Objective To evaluate the relation between adherence to drug therapy, including placebo, and mortality.

Design Meta-analysis of observational studies.

Data sources Electronic databases, contact with investigators, and textbooks and reviews on adherence.

Review methods Predefined criteria were used to select studies reporting mortality among participants with good and poor adherence to drug therapy. Data were extracted for disease, drug therapy groups, methods for measurement of adherence rate, definition for good adherence, and mortality.

Results Data were available from 21 studies (46 847 participants), including eight studies with placebo arms (19 633 participants). Compared with poor adherence, good adherence was associated with lower mortality (odds ratio 0.56, 95% confidence interval 0.50 to 0.63). Good adherence to placebo was associated with lower mortality (0.56, 0.43 to 0.74), as was good adherence to beneficial drug therapy (0.55, 0.49 to 0.62). Good adherence to harmful drug therapy was associated with increased mortality (2.90, 1.04 to 8.11).

Conclusion Good adherence to drug therapy is associated with positive health outcomes. Moreover, the observed association between good adherence to placebo and mortality supports the existence of the “healthy adherer” effect, whereby adherence to drug therapy may be a surrogate marker for overall healthy behaviour.

Introduction

About one in four people do not adhere well to prescribed drug therapy.¹ Following principles of evidence based medicine, clinicians use the most relevant and available evidence to guide decisions on drug therapy. Once the prescription is written, however, the fate of drug therapy is with the patient. Poor adherence is considered a critical barrier to treatment success and remains one of the leading challenges to healthcare professionals.²

Much of the literature on adherence focuses on methods for measuring adherence and identification of risk factors for poor adherence,^{3–6} with the premise that good adherence must be associated with good health outcomes.⁷ Although the most detailed systematic review on adherence in the literature included a wide array of disease states, drug therapy was only one element within a range of therapeutic interventions.⁷ Combining adherence to drug therapy with adherence to other behavioural and therapeutic interventions limits the ability to examine specifically the relation between adherence to drug therapy and health outcomes.

Ideally the effect of adherence should be measured on an objective health outcome, such as mortality. Individual studies have reported that good adherence to prescribed drug therapy—even to placebo—was associated with a lower risk of mortality.^{w1–w3} This is contrary to the proposition that a placebo has little effect on health outcomes⁸ and has led to speculation that adherence to drug therapy may act as an identifiable marker for overall healthy behaviour, the so called healthy adherer effect.^{w1–w4 8–10} We tested this hypothesis by summarising published observations of the relation between adherence to drug therapy and mortality, with a particular interest in placebo arms of controlled studies.

Methods

We used standard systematic review methods.¹¹ Eligible for inclusion in our study were randomised controlled trials, retrospective analyses of data from randomised controlled trials, and observational studies evaluating the association between adherence to drug therapy and mortality. We applied no language restrictions.

A professional librarian (JV) carried out the literature search. She searched several electronic databases from inception date to 20 June 2005: Allied and Complementary Medicine (AMED), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Embase, Educational Research Information Center (ERIC), HealthSTAR, Medline, PsycINFO, and the Web of Science. Articles were identified using synonyms for adherence and mortality as database specific subject headings and keywords. We also checked references from textbooks^{12–14} and review articles^{1 7 9 10 15–17} on adherence for additional articles.

After excluding editorials, conference proceedings, letters, news articles, government reports, and practice guidelines, two investigators (SHS, DTE) independently screened titles and abstracts to identify potentially relevant citations. A citation was retained for further evaluation if either investigator selected it. Citations were excluded that did not report original data, have human participants, evaluate drug adherence, or report patient adherence.

Each potentially relevant article was reviewed to determine if it met the following inclusion criteria: described original research, explained the method used to measure adherence (for example, self report, electronic drug event monitoring system, pharmacy refill data, clinician estimation, tablet count), provided a clear definition for good adherence, stratified patients into good and poor adherence groups, and reported mortality

Web references w1–w22 and author details are on bmj.com

according to adherence groups. Discrepancies were resolved by majority vote after review by a third investigator (JAJ).

Inter-reviewer agreement was measured during the initial screen to identify potentially relevant citations and on review of the full articles for study inclusion.¹⁸ We characterised level of agreement using a qualitative scale developed by Landis and Koch.¹⁹

Data collection and outcome measures

Two investigators (DTE, RSP) used standardised forms to extract data from the included articles for disease state, drug therapy groups, methods used to measure adherence, definition for good adherence, and mortality. Accuracy of data collection was verified by comparing forms. We used the study authors' definition to stratify participants into good and poor adherence groups. When the number of deaths according to adherence group was not specifically stated in the article, we calculated this value from available information. If there was insufficient information in the article to calculate mortality according to adherence group, we contacted the corresponding author. The study was excluded if we were unable to obtain from the authors the number of deaths in each adherence group.

Statistical analysis

We analysed data using Rev Man 4.2.7. Each treatment arm in a randomised controlled trial was considered a discrete analysis of the relation between adherence and mortality. We used a random effects model to calculate pooled odds ratios and 95% confidence intervals.²⁰ Given the inclusion criteria, we anticipated including studies of a variety of diseases; therefore we examined heterogeneity using the Q and I² statistics.^{20–21} We used a variation of Tobias' method to evaluate changes to the pooled odds ratio and tests for heterogeneity.²² Rather than removing one study at a time, we used predetermined subgroups to identify potential sources of heterogeneity. For example, to test the theory of a healthy adherer effect,^{w1-w4 8–10} we constructed a separate model to summarise the association between adherence to placebo and mortality. A priori subgroups included the effect of active treatment compared with placebo, study design, disease state,

method used to measure adherence, and definition for good adherence.

Results

Overall, 6231 unique citations were identified and 1140 ones related to non-studies were removed. In total, 5012 citations were excluded after review of the title and abstract (fig 1). Agreement to identify potentially relevant articles was 0.68, which is considered "substantial."¹⁹ From the 79 potentially relevant articles, 21 studies with 46 847 participants met the inclusion criteria.^{w1-w21} Agreement at this stage was 0.97, considered "almost perfect."¹⁹

Supplemental information on mortality was obtained from multiple sources for some studies. In the University Group Diabetes Program, mortality for participants with good adherence was available in a paper on statistical methods.^{w18 w22} Supplemental mortality data according to adherence group were obtained from five corresponding authors.^{w5 w7 w9 w10 w15}

Eight studies were randomised, placebo controlled trials (37 701 participants) reporting mortality according to adherence group for each treatment arm in a retrospective analysis.^{w1-w4 w8 w16-w18 w22} Thirteen cohort studies (9146 participants) reported mortality according to adherence groups.^{w5-w7 w9-w15 w19-w21} Table 1 lists the characteristics of the included studies. Eight studies evaluated drug therapy in participants with a recent myocardial infarction,^{w1-w8} seven studies were in patients infected with HIV,^{w9-w15} and two studies were in primary prevention of heart disease.^{w16 w17} The remaining studies evaluated adherence to drug therapy for patients with type 2 diabetes,^{w18 w22} hyperlipidaemia,^{w19} heart failure,^{w20} and immune suppression after heart transplant.^{w21} Fifteen studies reported an adherence rate threshold to define good adherence.^{w1-w5 w7 w8 w11 w13-w19 w22} All cause mortality was the primary outcome in nine studies,^{w2 w3 w9-w13 w15 w19} and a secondary outcome in 12.^{w1 w4 w5-w8 w14 w16-w18 w20-w22} The adherence substudy for the cardiac arrhythmia suppression trial reported arrhythmic mortality according to adherence group.^{w4} Although 67% of the deaths in this trial were attributable to an arrhythmia, data for all cause mortality were not available.^{w4 23}

Fig 1 Flow of articles identified and studies included in review

Table 1 Characteristics of included studies in meta-analysis of adherence to drug therapy and mortality

Study	Study type	Treatment groups (No of participants)	Adherence measures	Threshold for good adherence	Observation period
Post-myocardial infarction management:					
Coronary Drug Project Research Group 1980 ^{w1}	Randomised controlled trial	Placebo (2695), clofibrate (1065)	Pill count, clinician's impression	≥80%	≥5 years
Wei et al 2002 ^{w5}	Cohort	Statins (427)	Pharmacy refill	≥80%	Average 2.4 years
Cotter et al 2004 ^{w6}	Cohort	Acetylsalicylic acid (64)	Thromboxane blood level	Less than healthy volunteer	1 year
β blocker heart attack trial (men) 1990 ^{w2}	Randomised controlled trial	Placebo (1094), propranolol (1081)	Pill count	>75%	1 year
β blocker heart attack trial (women) 1993 ^{w3}	Randomised controlled trial	Placebo (240), propranolol (265)	Pill count	≥75%	Median 26 months
Wei et al 2004 ^{w7}	Cohort	β blockers (386)	Pharmacy refill	≥80%	Median 3.7 years
Canadian amiodarone myocardial infarction arrhythmia trial 1999 ^{w8}	Randomised controlled trial	Placebo (538), amiodarone (573)	Pill count	≥66%	2 years
Cardiac arrhythmia suppression trial 1996 ^{w4}	Randomised controlled trial	Placebo (579), encainide or flecainide (574)	Pill count	>80%	Average 10 months
HIV infection:					
San Andres Rebollo et al 2004 ^{w9}	Cohort	Antiretroviral therapy (950)	Self report	Continued use	8 years
Cohn et al 2002 ^{w10}	Cohort	Antiretroviral therapy (626)	Self report	No missed doses in previous 48 hours	56 weeks
Garcia de Olalla et al 2002 ^{w11}	Cohort	Antiretroviral therapy (1219)	Self report and pharmacy refill	≥90%	3 years
Grimwade et al 2005 ^{w12}	Cohort	Cotrimoxazole prophylaxis (1288)	Self report and frequency of clinic visits	Continued use, collection of new tablet supply, and ongoing attendance at clinic	6 months
Hogg et al 2002 ^{w13}	Cohort	Antiretroviral therapy (1282)	Pharmacy refill	≥75%	1 year
Paterson et al 2000 ^{w14}	Cohort	Protease inhibitors (81)	Medication event monitoring system	≥95%	Median 6 months
Wood et al 2003 ^{w15}	Cohort	Antiretroviral therapy (1422)	Pharmacy refill	≥75%	4 years
Primary prevention of cardiovascular disease:					
Physicians' health study 1994 ^{w16}	Randomised controlled trial	Placebo (10 989), acetylsalicylic acid (11 004)	Self report	≥95%	Average 60.2 months
West of Scotland prevention study 1997 ^{w17}	Randomised controlled trial	Placebo (3293), pravastatin (3302)	Pill count	≥75%	Mean 4.9 years
Other disease states:					
University Group Diabetes Project 1970 ^{w22} 1971 ^{w18} (type 2 diabetes)	Randomised controlled trial	Placebo (205), tolbutamide (204)	Clinician's impression	≥75%	≥75% followed for ≥5 years
Howell et al 2004 ^{w19} (hypercholesterolaemia)	Cohort	Statins (869)	Pharmacy refill	≥80%	11 years
Miura et al 2001 ^{w20} (heart failure)	Cohort	Digoxin (431)	Blood levels of drug	Therapeutic range	72 months
Dobbels et al 2004 ^{w21} (heart transplant)	Cohort	Immunosuppressive regimen(101)	Medication event monitoring system (for cyclosporin use)	No variation in dose compliance and no drug holidays	5 years

The primary analysis of mortality risk according to adherence group was based on 2779 (5.9%) deaths in 46 847 participants. Overall, 1462 (4.7%) deaths occurred in 31 439 participants with good adherence to drug therapy and 1317 (8.5%) deaths in 15 408 participants considered to have poor adherence. The pooled odds ratio for mortality for good adherence compared with poor adherence was 0.56 (95% confidence interval 0.50 to 0.63). Some degree of heterogeneity was found: Q statistic $P=0.08$ and $I^2=28.6\%$.

The placebo arms from eight studies contained 19 633 participants and reported 996 (5.1%) deaths.^{w1-w4 w8 w16-w18 w22} Overall, good adherence to placebo was associated with a lower risk of mortality: pooled odds ratio 0.56, 0.43 to 0.74 (fig 2). Some heterogeneity of effect was found in this analysis: Q statistic $P=0.05$ and $I^2=51.2\%$. A subgroup analysis restricted to studies of drug therapy after myocardial infarction reduced variance substantially: Q statistic $P=0.79$ and $I^2=0\%$.^{w1-w4 w8} The pooled odds ratio of these five studies was 0.45 (0.38 to 0.54).

Two studies were identified in which active drug therapy increased the risk of mortality compared with placebo.^{w22 w23} Therefore separate models were constructed to summarise the

effect of adherence to active drug therapy found to be harmful compared with beneficial (fig 3). The two studies evaluating adherence to harmful drug therapy reported 53 (6.8%) deaths in 778 participants.^{w4 w18 w22} The pooled odds ratio for mortality was 2.90 (1.04 to 8.11) for participants with good compared with poor adherence to the active treatment (fig 3).

The association between adherence to proved beneficial drug therapy and mortality was reported in 19 studies involving 26 436 participants and 1730 (6.5%) deaths.^{w1-w3 w5-w17 w19-w21} The pooled odds ratio from these studies was 0.55 (0.49 to 0.62) for mortality in participants with good adherence compared with poor adherence (fig 3). These observations were homogeneous (Q statistic $P=0.71$ and $I^2=0\%$) and further stratification by study characteristics did not result in substantive changes to these relations (table 2). However, moderate variance of the observed effects was found among the seven HIV studies ($I^2=50.2\%$) and among the four studies that used subjective methods to measure adherence ($I^2=61.0\%$).²¹ Minor variance ($I^2=8.6\%$) was found among the 13 cohort studies (table 2).²¹

Research

Discussion

This meta-analysis of 21 studies, involving 46 847 participants, showed a consistent association between adherence to drug therapy and mortality. For participants with good adherence to placebo or beneficial drug therapy, the risk of mortality was

about half that of participants with poor adherence. Conversely, the risk of mortality was more than doubled for participants with good adherence to proved harmful drug therapy compared with participants with poor adherence.

Fig 2 Association between adherence to placebo and mortality

Fig 3 Association between adherence to harmful or beneficial drug therapy and mortality

Table 2 Subgroup analysis of active treatment arms considered beneficial

Analysis group	No of studies	Pooled odds ratio (95% CI)	Tests for heterogeneity	
			P value (Q statistic)	I ² (%)
Active treatment arm considered beneficial	19	0.55 (0.49 to 0.62)	0.71	0
Post-myocardial infarction studies only ^{w1-w3 w5-w8}	7	0.52 (0.41 to 0.66)	0.96	0
HIV studies only ^{w9-w15}	7	0.53 (0.41 to 0.69)	0.06	50.2
Primary prevention studies only ^{w16 w17}	2	0.58 (0.46 to 0.73)	0.99	0
Method used to measure adherence:				
Objective method (pill count, pharmacy refill, blood level, medication event monitor system) ^{w1-w3 w5-w8 w11 w13-w15 w17 w19-w21}	15	0.53 (0.46 to 0.60)	0.99	0
Subjective method (patient self report, clinician impression) ^{w9 w10 w12 w16}	4	0.55 (0.37 to 0.83)	0.05	61.0
Threshold used to define good adherence group:				
≥75% ^{w1-w3 w5 w7 w11 w13-w17 w19}	12	0.54 (0.48 to 0.61)	0.97	0
≥80% ^{w1 w5 w7 w11 w14 w16 w19}	7	0.58 (0.50 to 0.68)	1.00	0
≥90% ^{w11 w14 w16}	3	0.60 (0.49 to 0.73)	0.91	0
Study design:				
Randomised controlled studies only ^{w1-w3 w5 w16 w17}	6	0.55 (0.46 to 0.65)	0.95	0
Cohort studies only ^{w5-w7 w9-w15 w19-w21}	13	0.55 (0.47 to 0.64)	0.36	8.6

The association between adherence to harmful therapy and mortality is important in the light of recent issues of patient safety and post-marketing drug surveillance. Our observation suggests that stratification by adherence group may facilitate earlier identification of harmful therapies if the rate of adverse events is higher in participants with good adherence. According to the consolidated standards of reporting trials statement, investigators should, at a minimum, report the number of participants receiving the intended treatment.²⁴ Although randomised clinical trials will often measure adherence—either through pill count from returned vials or information on frequency of refills—this information is usually reported only as an overall adherence rate.²⁵ Many authors have identified that an array of adherence rates can confound the association between treatment and response and substantially affect generalisability.^{25–27} Therefore we would encourage clinical trialists to consider reporting treatment effects stratified by adherence group.

In 1997 McDermott and colleagues reviewed the literature on cardiovascular disease that reported admission to hospital and mortality according to adherence groups.⁹ They found that seven of 12 studies had a significant association between adherence and outcomes and noted that adherence to placebo was associated with improved outcomes in three studies. More recently DiMatteo and colleagues determined that the risk of a poor health outcome was 26% lower in participants with good adherence.⁷ Although that meta-analysis included studies from a wide range of medical conditions, drug therapy was included with a variety of other healthcare interventions. In addition, the placebo arms from controlled trials were excluded from their analysis. Our study confirms, updates, and extends these observations by including studies from across several disease states and summarises the observations between adherence to drug therapy (both active drug and placebo) and mortality.

Our study shares limitations inherent with meta-analyses in general and with studies of adherence specifically. Firstly, important studies relevant to the research question may have been missed during the literature search, although this was unlikely. Secondly, as with previous reviews,^{7–9} our data sources were observational studies, thus restricting our ability to explore fully the influence of unmeasured confounding variables. For example, participants with good adherence to study drugs (even placebo) may also have good adherence to other healthy behaviours such as diet, exercise, regular follow-up with healthcare professionals, immunisations, screening, and use of other drugs.^{w1-w4 8–10} All of these could independently affect the risk of mortality. Conversely, participants with poor adherence may have consciously chosen to use a lower dosage^{28–29} or have other conditions, such as depression, that affect adherence.^{10–30} In the absence of individual patient data to control for these factors, we tested the healthy adherer effect hypothesis and assumed that the presence of good adherence is a marker for overall healthy behaviour.^{w1-w4 8–10} Thirdly, in the absence of an ideal method to measure adherence,³¹ we observed a wide variety of measurement methods and definitions for good adherence. Grouping studies according to measurement method and definition for good adherence did not, however, result in substantive changes to our overall observation. Finally, with the exception of two studies,^{w6 w20} all studies used indirect methods to measure adherence. These methods are limited by the assumption that drug acquisition is a reasonable surrogate for consumption. This assumption would, however, overestimate exposure and bias our observation towards the null.

With these limitations in mind, our findings support the tenet that good adherence to drug therapy is associated with positive health outcomes. Moreover, the observed association between good adherence to placebo and lower mortality also supports the existence of the healthy adherer effect, whereby adherence to drug therapy may be a surrogate marker for overall healthy behaviour. Our findings set the stage for future studies to address the causal relation between adherence and health outcomes, but, more importantly, quantify for patients and providers how important it is to take drugs of proved efficacy as prescribed.

We thank the individual trialists for providing information from their study databases and Maria Santana, who translated three Spanish papers.

Contributors: SHS had the idea for the article. All authors took part in the planning and design of the study. SHS, DTE, RSP, and JV did the data collection. MS (listed in the acknowledgements) assisted in data collection from articles printed in Spanish. SHS carried out the statistical analyses. SHS,

What is already known on this topic

About one in four people do not adhere well to prescribed drug therapy

Poor adherence is considered a critical barrier to treatment success and remains an important challenge to healthcare professionals

What this study adds

Good adherence to drug therapy is associated with positive health outcomes

The observed association between adherence to placebo and mortality supports the premise of a healthy adherer effect, where adherence to drug therapy may be a surrogate marker for overall healthy behaviour

DTE, SRM, RSP, RTT, and JAJ had access to the data and participated in the interpretation of the data. SHS wrote the first draft of the paper. SHS provided leadership for the study and is guarantor.

Funding: None.

Competing interests: None declared.

- 1 DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. *Med Care* 2004;42:200-9.
- 2 Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. *Circulation* 1997;95:1085-90.
- 3 Morris LS, Schulz RM. Patient compliance—an overview. *J Clin Pharm Ther* 1992;17:283-95.
- 4 Donovan JL. Patient decision making. The missing ingredient in compliance research. *Int J Technol Assess Health Care* 1995;11:443-55.
- 5 Ellis S, Shumaker S, Sieber W, Rand C. Adherence to pharmacological interventions. Current trends and future directions. The Pharmacological Intervention Working Group. *Control Clin Trials* 2000;21:S218-25.
- 6 Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med* 2005;353:487-97.
- 7 DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. *Med Care* 2002;40:794-811.
- 8 Czajkowski SM, Chesney MA, Smith AW. Adherence and the placebo effect. In: Shumaker SA, Schron EB, Ockene JK, eds. *The handbook of health behavior change*. New York: Springer, 1990:515-34.
- 9 McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. *Arch Intern Med* 1997;157:1921-9.
- 10 Hays RD, Kravitz RL, Mazel RM, Sherbourne CD, DiMatteo MR, Rogers WH, et al. The impact of patient adherence on health outcomes for patients with chronic disease in the medical outcomes study. *J Behav Med* 1994;17:347-60.
- 11 In: Higgins JPT, Green S, eds. *Cochrane handbook for systematic reviews of interventions* 4.2.5 [updated May 2005]. www.cochrane.dk/cochrane/handbook/hbook.htm (accessed 3 Apr 2006).
- 12 Shumaker SA, Schron EB, Ockene JK. *The handbook of health behavior change*. New York: Springer, 1990.
- 13 Cramer JA, Spilker B. *Patient compliance in medical practice and clinical trials*. New York: Raven, 1991.
- 14 Myers LB, Midence K. *Adherence to treatment in medical conditions*. Australia: Harwood Academic, 1998.
- 15 Cramer JA. A systematic review of adherence with medications for diabetes. *Diabetes Care* 2004;27:1218-24.
- 16 Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: a review of published and abstract reports. *Patient Educ Couns* 2002;46:93-108.
- 17 Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. *Top HIV Med* 2003;11:185-98.
- 18 Cohen JA. A coefficient of agreement for nominal scales. *Educ Psychol Meas* 1960;20:37-46.
- 19 Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159-74.
- 20 DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177-88.
- 21 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60.
- 22 Tobias A. Assessing the influences of a single study in meta-analysis. *Stata Tech Bull* 1999;47:15-7.
- 23 Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. *N Engl J Med* 1991;324:781-8.
- 24 Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. *JAMA* 2001;285:1987-91.
- 25 Boudes P. Drug compliance in therapeutic trials: a review. *Control Clin Trials* 1998;19:257-68.
- 26 Haynes RB, Dantes R. Patient compliance and the conduct and interpretation of therapeutic trials. *Control Clin Trials* 1987;8:12-9.
- 27 Efron B, Feldman D. Compliance as an explanatory variable in clinical trials. *J Am Stat Assoc* 1991;86:9-26.
- 28 Weintraub M. Intelligent noncompliance with special emphasis on the elderly. *Contemp Pharm Pract* 1981;4:8-11.
- 29 Conrad P. The meaning of medications: another look at compliance. *Soc Sci Med* 1985;20:29-37.
- 30 Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. *Arch Intern Med* 2000;160:3278-85.
- 31 Rudd P. In search of the gold standard for compliance measurement. *Arch Intern Med* 1979;139:627-8.

(Accepted 21 April 2006)

doi 10.1136/bmj.38875.675486.55

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta,
Edmonton, AB, Canada T6G 2N8

Scot H Simpson *assistant professor*

Institute of Health Economics, Edmonton, AB

Dean T Eurich *research associate*

Janice Varney *librarian*

Division of Internal Medicine, Department of Medicine, Faculty of Medicine and
Dentistry, University of Alberta

Sumit R Majumdar *associate professor*

Rajdeep S Padwal *assistant professor*

Division of Cardiology, Department of Medicine, Faculty of Medicine and
Dentistry, University of Alberta

Ross T Tsuyuki *professor*

Department of Public Health Sciences, Faculty of Medicine and Dentistry,
University of Alberta

Jeffrey A Johnson *professor*

Correspondence to: S H Simpson ssimpson@pharmacy.ualberta.ca